Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C Genotype 4

Journal of Viral Hepatitis

Volumn 26, Issue 2, 2019, Pages 263-270

  Abdel Ghaffar, Tawhida Y ^a,b   El Naghi, Suzan ^a,c   Abdel Gawad, Manal ^d   Helmy, Sarah ^a   Abdel Ghaffar, Aisha ^b   Yousef, Medhat ^e   Moafy, Mohamad ^b  

^a Yassin Abdelghaffar Charity Center for Liver Disease and Research   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

^c National Hepatology and Tropical Medicine Research Institute   (Egypt)

^d ALEXANDRIA UNIVERSITY   (Egypt)

^e Fibrosence Medical Center   (Egypt)

Author keywords

direct acting antiviral therapy; generic drug; hepatitis C virus; mixed genotypes; paediatric

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DACLATASVIR; DAKTAVIRA; GRATISOVIR; SOFOSBUVIR; ANTIVIRUS AGENT; IMIDAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; BLURRED VISION; CHILD; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; COHORT ANALYSIS; COUGHING; DECREASED APPETITE; DENTAL CARIES; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPEPSIA; FAINTNESS; FATIGUE; FEMALE; FEVER; FOLLOW UP; HAND PAIN; HEADACHE; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIPOMA; MALE; MOUTH ULCER; MUSCULOSKELETAL PAIN; MYALGIA; NONHUMAN; NOSE OBSTRUCTION; PILOT STUDY; POST TREATMENT SURVIVAL; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; SUSTAINED VIROLOGIC RESPONSE; VOMITING; COMBINATION DRUG THERAPY; DRUG EFFECT; GENETICS; GENOTYPE; HEPACIVIRUS; MULTIMODALITY CANCER THERAPY; VIROLOGY;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE;

EID: 85058047632     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.13032     Document Type: Article

References (53)

1. Kouyoumjian SP, Chemaitelly H, Abu-Raddad LJ. Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions. Sci Rep. 2018;8(1):1661
2. Mohamoud YA, Mumtaz GR, Riome S, Miller DW, Abu LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis. 2013;13:288
3. Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017;14(2):122-132
4. Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22(34):7824-7840
5. World Health Organization. Global hepatitis report (WHO, 2017)
6. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333-1342
7. Squires JE, Balistreri WF. Hepatitis C virus infection in children and adolescents. Hepatol Commun. 2017;1(2):184-187
8. Wantuck JM, Ahmed A, Nguyen MH. Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther. 2014;39:137-147
9. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77-87
10. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:S45-S57
11. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout egypt. J Infect Dis. 2000;182:698-707
12. Schwarz KB, Gonzalez-Peralta RP, Murray KF, et al. Peginterferon with or without ribavirin for chronic hepatitis C in children and adolescents: final results of the Peds-C trial. Hepatology. 2008;48:418A
13. Abdel Ghaffar TY, Suzan El Naghy S, El Sebaie H, El Monaiery M, Abdel Ghaffar AY. Pegylated α interferon 2B plus ribavirin in the treatment of HCV genotype 4 infection. Indian J Pediatr 2009;76:895
14. El Naghi S, Mahmoud F. Study of outcome of naïve and previous nonresponder hepatitis C virus Egyptian children treated with combined therapy of pegylated interferon plus ribavirin. Egypt Liver J. 2014;4(3):87-93
15. USDoHaHSFaDACfDEaR. Guidance for Industry Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Drugs for Treatment 2013. Available from: URL: http://www.fda. gov/downloads/drugs/guidancecomplianceregulatoryinformation/ guidances/ucm225333.pdf
16. Peter J, Nelson DR. Optimal interferon-free therapy in treatment experienced chronic hepatitis C patients. Liver Int. 2015;35(Suppl 1):65-70
17. Office of the Commissioner. Press Announcements - FDA approves two hepatitis C drugs for pediatric patients. U S Food and Drug Administration Home Page. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm551407.htm. Published April 7, 2017. Accessed April 29, 2018
18. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461-511
19. American Association for the Study of Liver Diseases. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Available from: https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/HCVGuidance_May_24_2018a.pdf. Published May 24, 2018. Accessed July 31, 2018
20. Pol S, Corouge M, Vallet-Pichard A. Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life. Hepat Med. 2016;8:21-26
21. Kish T, Aziz A, Sorio M. Hepatitis C in a new era: a review of current therapies. P T. 2017;42(5):316-329
22. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211-221
23. Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63(5):1493-1505
24. Liao H, Tan P, Zhu Z, Yan X, Huang J. Sofosbuvir in combination with daclatasvir in liver transplant recipients with HCV infection: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41(3):262-271. Epub 2017 Jan 9
25. Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:714-725
26. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61:1127-1135
27. Ahmed OA, Elsebaey MA, Fouad MHA, et al. Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection. Infect Drug Resist. 2018;11:441-445. eCollection 2018
28. El-Khayat H, Fouad Y, Mohamed HI, et al. Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4. Aliment Pharmacol Ther. 2018;47(5):674-679. Epub 2018 Jan 3
29. Yakoot M, Abdo AM, Abdel-Rehim S, Helmy S. Response tailored protocol versus the fixed 12 weeks course of dual sofosbuvir/daclatasvir treatment in Egyptian patients with chronic hepatitis C genotype-4 infection: a randomized, open-label, non-inferiority trial. EBioMedicine. 2017;21:182-187. Epub 2017 May 17
30. Omar H, El Akel W, Elbaz T, et al. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18378 patients in Egypt. Aliment Pharmacol Ther. 2018;47(3):421-431. Epub 2017 Nov 29
31. Ossama AA, et al. Sofosbuvir Plus daclatasvir in treatment of chronic hepatitis C genotype 4 infection in a cohort of Egyptian patients: an experiment the size of egyptian village. Int J Hepatol. 2018;2018:9616234
32. Abdel-Aziz AM, Ibrahim MA, El-Sheikh AA, et al. Effect of sofosbuvir plus daclatasvir in hepatitis C virus genotype-4 patients: promising effect on liver fibrosis. J Clin Exp Hepatol 2018;8(1):15-22
33. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696
34. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518-526
35. Rewisha EA, Elsabaawy MM, Elshaarawy O, Abdallah A, Elsabaawy DM, Alhaddad OM. Hepatocellular carcinoma following direct anti-viral for hepatitis C treatment: a report of an Egyptian case series. Hepatoma Res. 2017;3:178-181
36. Wirth S, et al. Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology. 2017;66(4):1102-1110. Epub 2017 Aug 26
37. El-Khayat HR, Kamal EM, El-Sayed MH, et al. The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience. Aliment Pharmacol Ther. 2018;47(6):838-844
38. Yakoot M, El-Shabrawi MH, AbdElgawad MM, et al. Dual sofosbuvir/daclatasvir therapy in adolescent patients with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr. 2018;67(1):86-89 [Epub ahead of print]
39. El-Shabrawi M, Abdo AM, El-Khayat H, Yakoot M. Shortened 8 Weeks Course of Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients, with Chronic Hepatitis C Infection. J Pediatr Gastroenterol Nutr. 2017;66(3):425-427
40. Balistreri WF, Murray KF, Rosenthal P, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology. 2017;66(2):371-378. Epub 2017 Jun 19
41. Smith SK, Rosenthal P. Clearance of hepatitis C virus after fixed-dose combination ledipasvir/sofosbuvir in an adolescent female with decompensated cirrhosis. J Pediatr Gastroenterol Nutr. 2016;63(5):516-517
42. Graf Einsiedel H, Christiansen H, Wiegand J. Letter to the editor: eight weeks treatment with sofosbuvir/ledipasvir in a 4-year-old child with chronic hepatitis C virus genotype 1 infection. Pediatr Infect Dis J. 2016;35(12):1373
43. Gowin E, Bereszyńska I, Adamek A, et al. The prevalence of mixed genotype infections in Polish patients with hepatitis C. Int J Infect Dis. 2016;43:13-16
44. Attaullaha S, Khan S, Zahid M. Letter to the Editor: heterogeneous distribution of HCV genotypes and growing menace of mixed HCV infection in blood recipients in Khyber Pakhtunkhwa. Braz J Infect Dis. 2017;21(4):489-490
45. McNaughton AL, Sreenu VB, Wilkie G, Gunson R, Templeton K, Leitch ECM. Prevalence of mixed genotype hepatitis C virus infections in the UK as determined by genotype-specific PCR and deep sequencing. J Viral Hepat. 2017;25(5):524-534 [Epub ahead of print]
46. McNaughton AL, et al. Mixed genotype hepatitis C infections and implications for treatment. Hepatology. 2014;59(3):1209
47. Cunningham EB, Applegate TL, Lloyd AR, Dore GJ, Grebely J. Mixed HCV infection and reinfection in people who inject drugs–impact on therapy. Nat Rev Gastroenterol Hepatol. 2015;12(4):218-230. Epub 2015 Mar 17
48. Ghani E, Noor M. Letter to the Editor: hepatitis C virus infection with multiple genotypes. J Coll Physicians Surg Pak. 2017;27(6):380-381
49. Rodriguez-Frias F, Nieto-Aponte L, Gregori J, et al. High HCV subtype heterogeneity in a chronically infected general population revealed by high-resolution hepatitis C virus subtyping. Clin Microbiol Infect. 2017;23(10):775.e1-775.e6. Epub 2017 Feb 10
50. Ahmed Sakr A, Hanifi JM, Valerie Lin M. Successful treatment of mixed hepatitis C genotypes in a cirrhotic patient with an all-oral, interferon-free regimen. ACG Case Rep J. 2017;4:e16
51. Ghaderi-Zefrehi H, Gholami-Fesharaki M, Sharafi H, Sadeghi F, Alavian SM. The distribution of hepatitis C virus genotypes in middle eastern countries: a systematic review and meta-analysis. Hepat Mon. 2016;16(9):e40357
52. Al-Balwi MA. Prevalence of mixed hepatitis C virus (HCV) genotypes among recently diagnosed dialysis patients with HCV infection. Saudi J Kidney Dis Transpl. 2011;22(4):712-716
53. Farag MM, Sofy AR, Mousa AA, Ahmed MA, Alganzory MR. Molecular assay and genotyping of hepatitis C virus among infected Egyptian and Saudi Arabian patients. Virology 2015;6:1-10